Upgrade to SI Premium - Free Trial

Sanofi (SNY) Announces Plans to Reture Auvi-Q Rights to kaléo

February 23, 2016 4:56 PM
Sanofi (NYSE: SNY) announced that the license and development agreement between Sanofi and kaléo, formerly Intelliject Inc., the developer of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles